首页> 外文期刊>JMIR Research Protocols >Tailored Medication Adherence Incentives Using mHealth for Children With High-Risk Asthma (TAICAM): Protocol for a Randomized Controlled Trial
【24h】

Tailored Medication Adherence Incentives Using mHealth for Children With High-Risk Asthma (TAICAM): Protocol for a Randomized Controlled Trial

机译:使用MEHEALT的儿童为具有高风险哮喘(TAICAM)的儿童量身定制的药物申请奖励奖励激励措施:随机对照试验的议定书

获取原文
获取外文期刊封面目录资料

摘要

Background Poor adherence to inhaled corticosteroid medications for children with high-risk asthma is both well documented and poorly understood. It has a disproportionate prevalence and impact on children of minority demographics in urban settings. Financial incentives have been shown to be a compelling method to engage those in a high-risk asthma population, but whether adherence can be maintained by offering financial incentives and how these incentives can be used to sustain high adherence are unknown. Objective The aim of this study is to determine the marginal effects of a financial incentive–based intervention on inhaled corticosteroid adherence, health care system use, and costs. Methods Participants include children aged 5 to 12 years who have had either at least two hospitalizations or one hospitalization and one emergency department visit for asthma in the year prior to their enrollment (and their caregivers). Participants are given an electronic inhaler sensor in order to track their medication use over a period of 7 months. After a 1-month period of observation, participants are randomized to 1 of 3 arms for a 3-month period. Participants in arm 1 receive daily text message reminders, feedback, and gain–framed, nominal financial incentives; participants in arm 2 receive daily text message reminders and feedback only, and participants in arm 3 receive no reminders, feedback, or incentives. All participants are subsequently observed for an additional 3-month period with no reminders, feedback, or incentives to assess whether any sustained effects are apparent. Results Study enrollment began in September 2019 with a target sample size of N=125 children. As of June 2020, 61 children have been enrolled. Data collection is estimated to be completed in June 2022, and analyses will be completed by June 2023. Conclusions This study will provide data that will help to determine whether a financial incentive–based mobile health intervention for promoting inhaled corticosteroid use can be effective in patients with high-risk asthma over longer periods.
机译:背景,吸入具有高风险哮喘的儿童吸入皮质类固醇药物的粘附性差既有清算良好,理解得多。它对城市环境中的少数民族人口统计数据具有不成比例的流行和影响。已被证明财务激励措施是一种令人兴奋的方法,可以使用高风险哮喘人群的方法,但是否可以通过提供金融激励措施以及如何使用这些激励措施来维持高度依从性来维护依从性。目的本研究的目的是确定基于金融激励干预对吸入皮质类固醇,医疗保健系统使用和成本的边际效应。方法参与者包括5至12岁的儿童在入学前(及其护理人员)在年内至少有两个住院或一次住院治疗和一个急诊部门访问。参与者被赋予电子吸入器传感器,以便在7个月内跟踪其药物使用。在观察1个月的观察期后,参与者随机分为3个武器中的3个月。 ARM 1的参与者获得日常短信提醒,反馈和额定财务激励措施; ARM 2中的参与者仅接收日常短信提醒和反馈,ARM 3中的参与者没有收到提醒,反馈或激励。随后在额外的3个月内观察所有参与者,没有提醒,反馈或激励措施,以评估是否有任何持续影响是明显的。结果研究入学始于2019年9月,目标样本大小为n = 125名儿童。截至2020年6月,61名儿童已注册。数据收集估计将于6月2022年6月完成,分析将于6月2023日完成。结论本研究将提供有助于确定用于促进吸入皮质类固醇使用的金融激励的移动健康干预的数据是否有效高风险哮喘超过更长的时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号